ALDX Expects Data In Q3, CATB Tumbles On Study Data, Teva Gets FDA Panel Nod

Shares of Catabasis Pharmaceuticals Inc. (CATB) were down over 31% in extended trading on Tuesday, following failure of its phase IIa clinical trial of CAT-2054 for the treatment of hypercholesterolemia.

from RTT - Biotech http://ift.tt/1ZwBFPD
via IFTTT